Humana Inc. (NYSE:HUM - Get Free Report) announced a quarterly dividend on Wednesday, September 2nd. Investors of record on Friday, October 30th will be given a dividend of 0.885 per share by the insurance provider on Friday, November 27th. This represents a c) annualized dividend and a dividend yield of 0.9%. The ex-dividend date is Friday, October 30th.
Humana has raised its dividend by an average of 0.1%annually over the last three years. Humana has a dividend payout ratio of 24.1% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect Humana to earn $15.26 per share next year, which means the company should continue to be able to cover its $3.54 annual dividend with an expected future payout ratio of 23.2%.
Humana Price Performance
NYSE:HUM traded up $5.25 during mid-day trading on Wednesday, reaching $400.12. The stock had a trading volume of 1,138,234 shares, compared to its average volume of 1,718,160. Humana has a 12 month low of $163.11 and a 12 month high of $428.88. The stock has a market capitalization of $48.05 billion, a PE ratio of 37.85, a P/E/G ratio of 2.18 and a beta of 0.72. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.74 and a quick ratio of 1.74. The stock has a 50-day simple moving average of $386.76 and a two-hundred day simple moving average of $292.15.
Humana (NYSE:HUM - Get Free Report) last released its earnings results on Wednesday, July 29th. The insurance provider reported $7.61 earnings per share for the quarter, topping the consensus estimate of $7.27 by $0.34. The firm had revenue of $40.89 billion during the quarter, compared to analysts' expectations of $40.58 billion. Humana had a return on equity of 11.20% and a net margin of 0.88%.The company's quarterly revenue was up 26.2% on a year-over-year basis. During the same period in the prior year, the company earned $6.27 earnings per share. On average, equities analysts anticipate that Humana will post 9.12 earnings per share for the current year.
Analysts Set New Price Targets
HUM has been the subject of several recent analyst reports. Leerink Partners upgraded Humana from a "market perform" rating to an "outperform" rating and set a $513.00 price objective for the company in a research report on Thursday, July 30th. Deutsche Bank Aktiengesellschaft assumed coverage on Humana in a research note on Thursday, July 30th. They set a "hold" rating for the company. Truist Financial increased their target price on shares of Humana from $320.00 to $415.00 and gave the stock a "hold" rating in a report on Tuesday, July 14th. Needham & Company LLC began coverage on shares of Humana in a research note on Wednesday, May 20th. They issued a "buy" rating on the stock. Finally, Royal Bank Of Canada lifted their price target on shares of Humana from $246.00 to $415.00 and gave the company a "sector perform" rating in a report on Thursday, July 9th. Fourteen equities research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $403.91.
Check Out Our Latest Analysis on Humana
About Humana
(
Get Free Report)
Humana Inc NYSE: HUM is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana's products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.
In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Humana, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humana wasn't on the list.
While Humana currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.